Accumulation of Krebs cycle intermediates and over-expression of HIF1α in tumours which result from germline FH and SDH mutations
Open accessThe DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index; 4 of the 15 sources its claims cite were checked for support.
Abstract
The nuclear-encoded Krebs cycle enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDHB, -C and -D), act as tumour suppressors. Germline mutations in FH predispose individuals to leiomyomas and renal cell cancer (HLRCC), whereas mutations in SDH cause paragangliomas and phaeochromocytomas (HPGL). In this study, we have shown that FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate. SDH-deficient tumours principally accumulate succinate. In situ analyses showed that these tumours also have over-expression of hypoxia-inducible factor 1alpha (HIF1alpha), activation of HIF1alphatargets (such as vascular endothelial growth factor) and high microvessel density. We found no evidence of increased reactive oxygen species in our cells. Our data provide in vivo evidence to support the hypothesis that increased succinate and/or fumarate causes stabilization of HIF1alpha a plausible mechanism, inhibition of HIF prolyl hydroxylases, has previously been suggested by in vitro studies. The basic mechanism of tumorigenesis in HPGL and HLRCC is likely to be pseudo-hypoxic drive, just as it is in von Hippel-Lindau syndrome.
Overview
CoChat Summary
TL;DR
This study provides in vivo evidence that germline FH and SDH mutations lead to accumulation of Krebs cycle intermediates and HIF1α over-expression in HLRCC and HPGL tumours, supporting pseudo-hypoxic drive as a shared tumorigenic mechanism. It also finds no evidence of increased reactive oxygen species in FH-deficient cells.
Key findings
- FH-deficient fibroblasts and HLRCC fibroids accumulate fumarate and succinate. FH-deficient fibroblast succinate was mean 59.4 mmol/g protein (median 39.8, range 32–125.9) versus controls mean 17.4 (median 14.5, range 9.9–29.8); HLRCC fibroids had succinate 70–98 and fumarate 417–688 mmol/g protein, with succinate:fumarate ratios of 0.10–0.22 versus >1 in myometria.
- SDH-deficient HPGL tumours principally accumulate succinate. SDHB-mutant paragangliomas had succinate 364.5 and 517.0 mmol/g protein versus non-HPGL tumours 32.3–49.7; one SDHB tumour (patient 4) did not show elevated succinate.
- HIF1α over-expression and HIF-target activation were seen in tumours: strong nuclear HIF1α in all HPGL tumours studied (12 paragangliomas and 4 phaeochromocytomas), moderate staining in HLRCC fibroids, and very strong staining in three renal cancers; VEGF expression was high and CD34 showed high microvessel density. Western blotting confirmed a 120 kDa HIF1α band only in tumour, not normal kidney.
- No notable increase in oxidative stress was found: SOD mean was 44.4 versus 38.2 mU/mg and reduced glutathione mean was 5.52 versus 4.04 nmol/mg in FH-deficient versus control cells, with retained mitochondrial complex I, II–III and IV activities.
Methods
- Metabolomic profiling used 1H MRS on skin fibroblasts from four fumarase deficiency patients and six controls, and GC/MS on frozen HLRCC fibroids, myometrium controls, and frozen paragangliomas plus non-HPGL controls.
- Mutation screening of SDHB, SDHC and SDHD was performed by direct sequencing, with array CGH for allelic loss; tumour analyses included HIF1α and CD34 immunohistochemistry, VEGF in situ hybridization, and HIF1α western blotting.
- Samples included HLRCC fibroids and renal cancers, HPGL paragangliomas and phaeochromocytomas, and normal myometrium/kidney controls, all collected with Research Ethics Committee approval.
Limitations
- The paper states that formal statistical analysis was problematic given the small number of samples and lack of information on underlying factors; tumour scarcity also meant duplicate metabolite analysis was not possible.
- The paper notes that one SDHB tumour failed to show elevated succinate for unclear reasons, that HPGL versus other tumour succinate differences were only just significant (P = 0.045) owing to sample 3, and that direct PHD inhibition by fumarate in HLRCC cannot be excluded.
- Evident from the text: HIF1α staining was also weak/moderate in surrounding myometrium, and the oxidative-stress conclusion rests on only two FH-deficient lines for SOD/glutathione assays.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 7 Not checked · 67 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“germline mutations in the B, C and D subunits of SDH predispose individuals to hereditary paragangliomatosis with phaeochromocytomas (HPGL) (2 -6)”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > INTRODUCTION
What the sources say
- Not checked yetcites [2] Baysal, B.E., Ferrell, R.E., Willett-Brozick, J.E., Lawrence, E.C., Myssiorek, D., Bosch, A., van der Mey, A., Taschner, P.E., Rubinstein, W.S., Myers, E.N. et al. (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science, 287, 848-851. source
- Not checked yetcites [3] Gimm, O., Armanios, M., Dziema, H., Neumann, H.P. and Eng, C. (2000) Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res., 60, 6822-6825.
- Not checked yetcites [4] Niemann, S. and Muller, U. (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat. Genet., 26, 268-270. source
- Partly supportedcites [5] Astuti, D., Latif, F., Dallol, A., Dahia, P.L., Douglas, F., George, E., Skoldberg, F., Husebye, E.S., Eng, C. and Maher, E.R. (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am. J. Hum. Genet., 69, 49-54. sourceExperimental — accuracy not yet measured
The Abstract and Results of Astuti et al. (2001) support the SDHB component strongly: inactivating germline SDHB mutations were found in eight families 'segregating pheochromocytoma with or without head and neck paraganglioma' plus one occult germline case, and the SDHD association is stated as background ('pheochromocytoma susceptibility has been associated with germline SDHD mutations'). The SDHC component is not this paper's finding: the Results state 'No pathogenic mutations were identified in SDHC' and 'there was no evidence of germline SDHC mutations in the kindreds with familial pheochromocytoma and paraganglioma', with the SDHC link credited to Niemann and Muller (2000) in the Discussion, and the Abstract hedges that SDHC and SDHD mutations 'may cause hereditary paraganglioma'. So the composite claim (B, C and D, stated as established predisposition) overstates what this source reports for SDHC. (LLM, conf=0.78)
- Not checked yetcites [6] Astuti, D., Douglas, F., Lennard, T.W., Aligianis, I.A., Woodward, E.R., Evans, D.G., Eng, C., Latif, F. and Maher, E.R. (2001) Germline SDHD mutation in familial phaeochromocytoma. Lancet, 357, 1181-1182. source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“neither our data nor those of Selak et al. (27) have provided evidence for an alternative model of tumorigenesis in HLRCC or HPGL based on increased levels of ROSs.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Partly supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. sourceExperimental — accuracy not yet measured
In “Reactive oxygen species do not play a role in HIF-1α induction after SDH inhibition” (page not available), Selak et al. report no detectable increase in ROS or change in glutathione redox state after SDH inhibition. That supports the statement as applied to the SDH-related HPGL model, but these data do not test the FH-related HLRCC model. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) showed that the mechanism for these findings may be inhibition by succinate of HIF PHDs, which rely for their activity on conversion of a-ketoglutarate to succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
The Introduction states that HIF prolyl hydroxylases use α-ketoglutarate and convert it to succinate during hydroxylation. In “Succinate is accumulated in SDH-inhibited cells,” the authors propose that accumulated succinate may inhibit this required reaction and impede PHD activity. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Selak et al. (27) tested a model of tumorigenesis in which raised levels of succinate caused increased HIF1a expression in vitro.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > DISCUSSION
What the sources say
- Supportedcites [27] Selak, M.A., Armour, S.M., MacKenzie, E.D., Boulahbel, H., Watson, D.G., Mansfield, K.D., Pan, Y., Simon, M.C., Thompson, C.B. and Gottlieb, E. (2005) Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell, 7, 77-85. source
In the section on succinate elevation and HIF-1α stabilization in cells (page unavailable), Selak et al. report that cells treated with a membrane-permeable succinate derivative had elevated HIF-1α levels under normoxic conditions. This supports the attributed in-vitro model; the measured increase was in HIF-1α protein levels, through stabilization. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“FH-deficient cells and tumours accumulate fumarate and, to a lesser extent, succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Abstract
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
40 more claims
Create a free account to see all 78 claims and to verify the 11 references still open.
- It may state two separate claims as one. 21
- Probably not a substantial claim. 14
- The quote only partly states this claim. 2
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevation of fumarate and succinate, such as in renal cancer subtypes bearing succinate dehydrogenase (SDH) or fumarate hydratase mutations, suppress HIF-α hydroxylation by the PHDs, resulting in the stabilization of both HIF-1α and HIF-2α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Intriguingly, unlike pVHL-deficient ccRCC tumors that constitutively express both HIF isoforms or HIF-2α preferentially, renal cancers bearing FH/SDH mutations tend to preferentially express HIF-1α [20].”
From The HIF Axes in Cancer - Angiogenesis, Metabolism and Immune-Modulation (2025) · cites this paper as [20]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, succinate and fumarate inhibit the prolyl hydroxylase domain-containing (PHD) enzymes that regulate stability of hypoxia-inducible factors (HIFs), such that FH and SDH deficient cancers activate the hypoxic gene expression program even under normoxic conditions (Hewitson et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Pollard et al., 2005
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To date, the clearest evidence that metabolites modulate HIF signaling comes from cells that are genetically defective in fumarate hydratase (FH) (Isaacs et al., 2005) or succinate hydrogenase (SDH; subunits b, c, and d) (MacKenzie et al., 2007; Pollard et al., 2005; Selak et al., 2005).”
From Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. (2008) · cites this paper as Pollard et al., 2005
In the citing paper
“For example, the increase in ROS induced by antimycin A can be abolished by adding either stigmatellin or myxothiazol (256).”
From Mitochondrial reactive oxygen species production in excitable cells: Modulators of mitochondrial and cell function (2009) · cites this paper as [256]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Increased succinate in HPGL tumours
“One SDHB tumour (patient 4) did not show elevated succinate.”
§ Accumulation of Krebs cycle intermediates and over-expression of HIF1a in tumours which result from germline FH and SDH mutations > Western blotting
“| 4 | No | 32.3 | 3.0 | 10.8 |”
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180 · cited 1×
“Mutations in VHL cause stabilization of the subunits of hypoxia-inducible factor (HIF) (18), which initiates the transcription of genes coding for pro-angiogenic proteins such as VEGF (19).”
BackgroundSuccinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase
Selak, M. A., Armour, S. M., MacKenzie, E. D., Boulahbel, H., Watson, D. G., Mansfield, K. D., Pan, Y., Simon, M. C., Thompson, C. B., & Gottlieb, E. (2005) · Cancer Cell · doi:10.1016/j.ccr.2004.11.022 · Cited by 2,108 · cited 4×
“Recently, support has been provided using an in vitro system for dysfunction of the Krebs cycle leading to the stabilization of HIF (27).”
BackgroundInfluentialMutations in SDHD , a Mitochondrial Complex II Gene, in Hereditary Paraganglioma
Baysal, B. E., Ferrell, R. E., Willett-Brozick, J. E., Lawrence, E. C., Myssiorek, D., Bosch, A., Mey, A. V. D., Taschner, P. E. M., Rubinstein, W. S., Myers, E. N., et al. (2000) · Science · doi:10.1126/science.287.5454.848 · Cited by 1,638
The Multiple Leiomyoma Consortium (2002) · Nature Genetics · doi:10.1038/ng849 · Cited by 1,635
Self-citationTransition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains
Riederer, P., Sofic, E., Rausch, W., Schmidt, B., Reynolds, G. P., Jellinger, K., & Youdim, M. B. H. (1989) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1989.tb09150.x · Cited by 1,383 · cited 1×
“Oxidative stress in FH-deficient and control cells was measured using a HPLC method to analyse the oxidation status of the antioxidant glutathione as previously described (33).”
Method[45] Cytochrome oxidase from beef heart mitochondria
Wharton, D. C., & Tzagoloff, A. (1967) · Methods in Enzymology · doi:10.1016/0076-6879(67)10048-7 · Cited by 1,261
Astuti, D., Latif, F., Dallol, A., Dahia, P. L. M., Douglas, F., George, E., Sköldberg, F., Husebye, E. S., Eng, C., & Maher, E. R. (2001) · The American Journal of Human Genetics · doi:10.1086/321282 · Cited by 1,087
Architecture of succinate dehydrogenase and reactive oxygen species generation
Yankovskaya, V., Horsefield, R., Törnroth, S., Luna-Chavez, C., Miyoshi, H., Léger, C., Byrne, B., Cecchini, G., & Iwata, S. (2003) · Science · doi:10.1126/science.1079605 · Cited by 927
Neumann, H. P. H. (2004) · JAMA · doi:10.1001/jama.292.8.943 · Cited by 893 · cited 1×
“SDHB mutations are associated with a higher proportion of malignant lesions and a relatively greater risk of phaeochromocytoma (8).”
Background
Cited by
Items 501–600 of 982
HIF-Mediated Hypoxic Response is Missing in Severely Hypoxic Uterine Leiomyomas
Mayer, A., Hoeckel, M., von Wallbrunn, A., Horn, L., Wree, A., & Vaupel, P. W. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-1241-1_58 · Cited by 29
“Expression of HIF-1a has, however, been demonstrated in leiomyomas from patients with the rare syndrome of hereditary leiomyoma and renal cell cancer (HLRCC, [ 10 ]).”
BackgroundProchilo, T., Savelli, G., Bertocchi, P., Abeni, C., Rota, L., Rizzi, A., & Zaniboni, A. (2013) · Case Reports in Oncology · doi:10.1159/000348429 · Cited by 28
Sánchez‐Heras, A. B., Castillejo, A., García-Díaz, J. D. D., Robledo, M., Teulé, À., Sánchez‐Martínez, R., Zúñiga, Á., Lastra, E., Durán, M., Llort, G., et al. (2020) · Cancers · doi:10.3390/cancers12113277 · Cited by 28
Multiple Hits for the Association of Uterine Fibroids on Human Chromosome 1q43
Aïssani, B., Wiener, H. W., & Zhang, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058399 · Cited by 27
“The current paradigm invokes upregulation of hypoxiainducible factors (HIF) and hypoxia responsive genes in tumors with reduced expression of mitochondrial FH, [14–17], however, the mechanism contributing to HIF activation (pseudo-hypoxic drive, increase in reactive oxygen species, defective apoptotic mechanism or ana…”
BackgroundFliedner, S. M. J., Brabant, G. E., & Lehnert, H. (2018) · Cell and Tissue Research · doi:10.1007/s00441-017-2760-3 · Cited by 28
“Accordingly, in FH-mutated renal cell carcinoma, succinate to fumarate levels were 0.1–0.2 (Pollard et al. 2005).”
BackgroundInfluentialJo, H. A., Hyeon, J. S., Yang, S. H., Jung, Y., Ha, H., Jeong, C. W., Kwak, C. H., Kim, Y., Lee, H., Lee, J. P., et al. (2020) · Kidney International · doi:10.1016/j.kint.2020.06.031 · Cited by 27
Role of microenvironment on neuroblastoma SK-N-AS SDHB-silenced cell metabolism and function
Rapizzi, E., Fucci, R., Giannoni, E., Canu, L., Richter, S., Cirri, P., & Mannelli, M. (2015) · Endocrine Related Cancer · doi:10.1530/erc-14-0479 · Cited by 28
“…as expected from the finding that succinate accumulation inhibits prolyl-hydroxylase activity and reduces HIF degradation (Dahia et al. 2005, Pollard et al. 2005, Selak et al. 2005, Koivunen et al. 2007, Favier et al. 2009, and, for recent reviews, see Richter et al. (2013) and Jochmanová…”
BackgroundHypoxia Pathway Mutations in Pheochromocytomas and Paragangliomas
Amorim-Pires, D., Peixoto, J., & Lima, J. P. (2016) · Cytogenetic and Genome Research · doi:10.1159/000457479 · Cited by 26
Uimari, O., Ahtikoski, A. M., Kämpjärvi, K., Bützow, R. C., Järvelä, I. Y., Ryynänen, M., Aaltonen, L. A., Vahteristo, P., & Kuismin, O. (2021) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.1111/aogs.14248 · Cited by 26
Research progress on the pathogenesis of the SDHB mutation and related diseases
Liu, C., Zhou, D., Yang, K., Xu, N., Peng, J., & Zhu, Z. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115500 · Cited by 26
Metabolic, autophagic, and mitophagic activities in cancer initiation and progression
Hjelmeland, A. B., & Zhang, J. (2016) · Biomedical Journal · doi:10.1016/j.bj.2015.10.002 · Cited by 26
“[105] Pollard PJ, Bri ere JJ, Alam NA, Barwell J, Barclay E, Wortham NC, et al.”
BackgroundFumarate integrates metabolism and immunity in diseases
Cheng, J., Xiao, Y., & Jiang, P. (2025) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.03.008 · Cited by 25
Canonical and new generation anticancer drugs also target energy metabolism
Rodríguez‐Enríquez, S., Gallardo‐Pérez, J. C., Hernández‐Reséndiz, I., Marín‐Hernández, Á., Pacheco-Velázquez, S. C., López‐Ramírez, S. Y., Rumjanek, F. D., & Moreno‐Sánchez, R. (2014) · Archives of Toxicology · doi:10.1007/s00204-014-1246-2 · Cited by 25
Kiss, N. B., Muth, A., Stenman, A., Juhlin, C. C., Geli, J., Bäckdahl, M., Höög, A., Wängberg, B., Nilsson, O., Ahlman, H., et al. (2012) · Endocrine Related Cancer · doi:10.1530/erc-12-0267 · Cited by 25
“This specific methylative inactivation of apoptotic and antiproliferative genes might instead mirror a physiological attempt to counter the state of pseudo-hypoxia, induced by SDH dysfunction and described in Pollard et al. (2005) and Cervera et al. (2008).”
BackgroundGenetic Kidney Cancer Syndromes
Ho, T. H., & Jonasch, E. W. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0129 · Cited by 25
Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis
Lussey‐Lepoutre, C., Buffet, A., Morin, A., Goncalves, J., & Favier, J. (2018) · Cell and Tissue Research · doi:10.1007/s00441-018-2797-y · Cited by 25
DNA Hydroxymethylation in Smoking-Associated Cancers
Nia, A. B., Caceres, A., & Tommasi, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052657 · Cited by 25
“Importantly, mutations in the tricarboxylic acid cycle enzymes succinate dehydrogenase (SDH) and fumarate hydratase (FH), which interconvert succinate and fumarate, respectively, are highly common in cancer [75,76].”
BackgroundNew Advances in the Genetics of Pheochromocytoma and Paraganglioma Syndromes
Gimenez‐Roqueplo, A. (2006) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1353.012 · Cited by 25
Zhang, R., Ji, J., Blaženović, I., Pi, F., Wang, T., Zhang, Y., & Sun, X. (2018) · Toxins · doi:10.3390/toxins10110441 · Cited by 24
Complex role of HIF in cancer: the known, the unknown, and the unexpected
Huang, E. L., Tiburcio, P. D. B., & Choi, H. (2014) · Hypoxia · doi:10.2147/hp.s50651 · Cited by 24
Birt–Hogg–Dubé: tumour suppressor function and signalling dynamics central to folliculin
Tee, A. R., & Pause, A. (2012) · Familial Cancer · doi:10.1007/s10689-012-9576-9 · Cited by 24
HIF Prolyl-4-hydroxylase Interacting Proteins: Consequences for Drug Targeting
Wenger, R. H., Camenisch, G., Stiehl, D. P., & Katschinski, D. M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649411 · Cited by 24
“Germline mutations of the genes encoding fumarate hydratase (FH) or succinate dehydrogenase (SDH) result in the accumulation of fumarate and succinate, respectively, two potent inhibitors of PHD activity [ 56 , 57].”
BackgroundOwens, K. M., Modica-Napolitano, J. S., & Singh, K. K. (2008) · Springer eBooks · doi:10.1007/978-0-387-84835-8_1 · Cited by 24
Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas
Sarkadi, B., Meszaros, K., Krencz, I., Canu, L., Krokker, L., Zakarias, S., Barna, G., Sebestyen, A., Papay, J., Hujber, Z., et al. (2020) · Cancers · doi:10.3390/cancers12030599 · Cited by 23
Zhang, X., Zhao, J., Yin, X., Liang, J., Wang, Y., Zheng, L., Tan, P., Lin, Y., Xu, N., Zhu, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59513-8 · Cited by 23
Châtre, L., Ducat, A., Spradley, F. T., Palei, A. C., Chéreau, C., Couderc, B., Thomas, K. C., Wilson, A. R., Amaral, L. M., Gaillard, I., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102406 · Cited by 23
The Role of Inflammation in Sarcoma
Radons, J. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-0348-0837-8_11 · Cited by 24
Genetically Modeled Mice with Mutations in Mitochondrial Metabolic Enzymes for the Study of Cancer
Piruat, J. I., & Millán‐Uclés, Á. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00200 · Cited by 23
“In favor of the“pseudo-hypoxia”hypothesis for tumorigenesis, a large amount of data exists showing activation of the hypoxia response in human tumors carrying these mutations (24, 72, 73).”
BackgroundThe Differential Diagnosis of Medullary-Based Renal Masses
Baniak, N., Tsai, H. K., & Hirsch, M. S. (2021) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2020-0464-ra · Cited by 23
Cellular Respiration and Carcinogenesis
Sarangarajan, R., & Apte, S. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-435-3 · Cited by 23
Metabolic Reprogramming and Its Relationship to Survival in Hepatocellular Carcinoma
Wang, Q., Tan, Y., Jiang, T., Wang, X., Li, Q., Li, Y., Dong, L., Liu, X., & Xu, G. (2022) · Cells · doi:10.3390/cells11071066 · Cited by 22
Hoekstra, A. S., Addie, R. D., Ras, C., Seifar, R. M., Ruivenkamp, C. A. L., Bruijn, I. H. B., Hes, F. J., Jansen, J. C., Corssmit, E. P. M., Corver, W. E., et al. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw218 · Cited by 22
Renal Carcinogenesis, Tumor Heterogeneity, and Reactive Oxygen Species: Tactics Evolved
Shanmugasundaram, K., & Block, K. L. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6569 · Cited by 22
“These studies led to the discovery that HIF1alpha is stabilized by succinate and fumarate metabolites that accumulate during the loss of FH and SDH genes, respectively (119).”
BackgroundLoss of sdhb in zebrafish larvae recapitulates human paraganglioma characteristics
Dona, M., Waaijers, S., Richter, S., Eisenhofer, G., Korving, J., Kamel, S. M., Bakkers, J., Rapizzi, E., Rodenburg, R. J., Zethof, J., et al. (2020) · Endocrine Related Cancer · doi:10.1530/erc-20-0308 · Cited by 22
Bernardo‐Castiñeira, C., Valdés, N., Celada, L., Martínez, A. S. J., Sáenz‐de‐Santa‐María, I., Bayón, G. F., Fernández, A. F., Sierra, M., Fraga, M. F., Astudillo, A., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01471 · Cited by 22
Metabolomics of cancer cell cultures to assess the effects of dietary phytochemicals
Brasili, E., & Filho, V. C. (2015) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2014.964799 · Cited by 21
“This unexpected low mortality has been attributed to the regular consumption of red wine, in line with epidemiological studies suggesting that a moderate intake of red wine reduced the risk of cardiovascular disease (Renaud and De Lorgeril, 1992).”
ResultHu, C., Zhao, Y., Wang, X., & Zhu, T. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651620 · Cited by 21
“MiR-122, 155, 21, and 210 Overexpression (predicted targets including HIF-1α, VEGF receptor 2, mTOR, etc.) PS Juan et al., 2010; White et al., 2011a MiR-200c, 335, 199, and 218 Downregulated (predicted targets including AKT, RAS, Rheb, etc.) PS Chow et al., 2010; White et al., 2011a MiR-141 and 200c Inhibit E-cadherin…”
BackgroundInfluentialVDACs Post-Translational Modifications Discovery by Mass Spectrometry: Impact on Their Hub Function
Pittalà, M. G. G., Nibali, S. C., Reina, S., Cunsolo, V., Francesco, A. D., Pinto, V. D., Messina, A. A., Foti, S., & Saletti, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222312833 · Cited by 21
Millán‐Uclés, Á., Castro, B. D., García‐Flores, P., Báez, A., Pérez‐Simón, J. A., López‐Barneo, J., & Piruat, J. I. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085528 · Cited by 21
“This change in gene expression seems to be mediated by a ‘‘pseudo-hypoxic’’ response in which Hif1a plays a central regulatory role [11,12,13].”
BackgroundCampione, E., Terrinoni, A., Orlandi, A., Codispoti, A., Melino, G., Bianchi, L., Mazzotta, A., Garaci, F. G., Ludovici, A., & Chimenti, S. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700851 · Cited by 21
Abushawish, K. Y. I., Soliman, S. S. M., Giddey, A. D., Al-Hroub, H. M., Mousa, M., Alzoubi, K. H., El‐Huneidi, W., Abu‐Gharbieh, E., Omar, H. A., Elgendy, S. M., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911975 · Cited by 20
Inflammatory stress and sarcomagenesis: a vicious interplay
Radons, J. (2013) · Cell Stress and Chaperones · doi:10.1007/s12192-013-0449-4 · Cited by 20
“HLRCC tumors overexpress HIF-1α and its targets such as vascular endothelial growth factor (VEGF ) accompanied by a higher microvessel density (Pollard et al. 2005).”
BackgroundSaskői, É., Hujber, Z., Nyírő, G., Likó, I., Mátyási, B., Petővári, G., Mészáros, K. V., Kovács, A., Patthy, L., Supekar, S., et al. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044925 · Cited by 20
“Following inhibition of PHD, HIF1α is not labeled for proteasomal degradation and active HIF favors pseudohypoxia-driven tumorigenesis through mal-activation of hypoxia-responsive genes such as vascular endothelial growth factor (VEGF; also known as VEGFA) or glucose transporter 1 (GLUT1; also known as SLC2A1) (Pollar…”
BackgroundRicketts, C. J., Killian, J. K., Vocke, C. D., Wang, Y., Merino, M. J., Meltzer, P. S., & Linehan, W. M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0278108 · Cited by 20
“Furthermore, increased fumarate inhibits the activity of prolyl hydroxylases that degrade the HIFα transcription factor subunits, resulting in a pseudo-hypoxic state that up-regulates many of the genes necessary to maintain the higher levels of glycolysis required by these tumors [13, 14].”
BackgroundSandhu, I. S., Maksim, N. J., Amouzougan, E. A., Gallion, B. W., Raviele, A. L. J., & Ooi, A. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150041 · Cited by 21
Casting an eye on the Krebs cycle
Münnich, A. (2008) · Nature Genetics · doi:10.1038/ng1008-1148 · Cited by 20
Oxygen sensors as therapeutic targets in kidney disease
Haase, V. H. (2017) · Néphrologie & Thérapeutique · doi:10.1016/j.nephro.2017.01.015 · Cited by 20
Rewiring of RNA methylation by the oncometabolite fumarate in renal cell carcinoma
Fitzsimmons, C. M., Mandler, M. D., Lunger, J. C., Chan, D., Maligireddy, S. S., Schmiechen, A. C., Gamage, S. T., Link, C. N., Jenkins, L. M. M., Chan, K. C., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcae004 · Cited by 20
Merlo, A., Bernardo‐Castiñeira, C., Sáenz‐de‐Santa‐María, I., Pitiot, A. S., Balbín, M., Astudillo, A., Valdés, N., Scola, B., Toro, R. D., Méndez‐Ferrer, S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14265 · Cited by 19
“Some reported transcription profiles have shown that SDHx-mutated PGLs (SDHx-PGLs) showed enrichment in genes associated with the HIFpathway and accumulate HIF-1α [13, 14] whereas others did not find such an association thus arguing against the pseudohypoxia hypothesis in SDHx-PGLs [11, 15, 16].”
BackgroundUntargeted and stable isotope-assisted metabolomic analysis of MDA-MB-231 cells under hypoxia
Yang, J., Cheng, J., Sun, B. H., Li, H., Wu, S., Dong, F., & Yan, X. (2018) · Metabolomics · doi:10.1007/s11306-018-1338-8 · Cited by 19
A patient with a germline SDHB mutation presenting with an isolated pituitary macroprolactinoma
Maher, M., Roncaroli, F., Mendoza, N., Meeran, K. M., Canham, N. L. E., Kosicka‐Slawinska, M., Bernhard, B., Collier, D., Drummond, J., Skordilis, K., et al. (2018) · Endocrinology Diabetes and Metabolism Case Reports · doi:10.1530/edm-18-0078 · Cited by 19
Silas, Y., Singer, E., Das, K., Lehming, N., & Pines, O. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2026595118 · Cited by 19
Hypothesis: Why Different Types of SDH Gene Variants Cause Divergent Tumor Phenotypes
Bayley, J., & Devilee, P. (2022) · Genes · doi:10.3390/genes13061025 · Cited by 20
Metabolic pathways in cancers: key targets and implications in cancer therapy
Vijayakumar, S. N., Sethuraman, S., & Krishnan, U. M. (2015) · RSC Advances · doi:10.1039/c5ra06505d · Cited by 19
Palu, R. A. S., Ong, E., Stevens, K., Chung, S., Owings, K. G., Goodman, A. G., & Chow, C. Y. (2019) · G3 Genes Genomes Genetics · doi:10.1534/g3.119.400722 · Cited by 19
“Mutations in these genes have been associated with ovarian cancer (OPCML) (Sellar et al. 2003), renal cancer (FH) (The Multiple Leiomyoma Consortium 2002; Pollard et al. 2005), and various carcinomas (TMEM259) (Chen et al. 2005).”
BackgroundZhao, Z., Rothery, R. A., & Weiner, J. H. (2006) · Biochemistry and Cell Biology · doi:10.1139/o06-188 · Cited by 18
“As mentioned earlier, metabolic imbalance and dysfunction of the tricarboxylic acid cycle can also trigger tumor formation (Briere et al. 2005, 2006; Dahia et al. 2005; Pollard et al. 2005; Selak et al. 2005; Vanharanta et al. 2006).”
BackgroundThe role of hypoxia inducible factor-1 in cell metabolism – a possible target in cancer therapy
Aiba, R. S. B., Dimova, E. Y., Görlach, A., & Kietzmann, T. (2006) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.10.4.583 · Cited by 19
“This enhanced HIF-1α stability might be one of the reasons for the inherited cancer syndromes observed in clinical cases characterised with SDH and FH mutations [115-120].”
BackgroundWang, Y., Liu, B., Li, F., Zhang, Y., Gao, X., Wang, Y., & Zhou, H. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1274239 · Cited by 18
Genetic mutations affecting mitochondrial function in cancer drug resistance
Lee, C., Park, S., & Yoon, S. K. (2023) · Genes & Genomics · doi:10.1007/s13258-022-01359-1 · Cited by 18
Wake, N. C., Ricketts, C. J., Morris, M. R., Prigmore, E., Gribble, S. M., Skytte, A., Brown, M. D., Clarke, N. W., Banks, R. E., Hodgson, S. V., et al. (2013) · Human Mutation · doi:10.1002/humu.22433 · Cited by 18
Self-citationMetabolic alteration in tumorigenesis
Yang, H., Xiong, Y., & Guan, K. (2013) · Science China Life Sciences · doi:10.1007/s11427-013-4549-2 · Cited by 18
Tanaka, T., Hirai, M., Watanabe, Y., & Kita, K. (2012) · Parasitology International · doi:10.1016/j.parint.2012.06.002 · Cited by 18
Heinritz, W., Paasch, U., Sticherling, M., Wittekind, C., Simon, J. C., Froster, U., & Renner, R. (2007) · Annals of Human Genetics · doi:10.1111/j.1469-1809.2007.00396.x · Cited by 18
Immunosurveillance of cancer cell stress
Lorenzo‐Herrero, S., Sordo‐Bahamonde, C., Gonzalez, S. R., & López‐Soto, A. (2019) · Cell Stress · doi:10.15698/cst2019.09.198 · Cited by 19
Huang, K. T., Dobrovic, A., & Fox, S. B. (2009) · BMC Research Notes · doi:10.1186/1756-0500-2-194 · Cited by 18
“[24] have suggested that overexpression of HIF-1α in normoxic conditions is due to the accumulation of succinate, which then is able to inhibit the activity of HIF-1α prolyl hydroxylases via product inhibition.”
BackgroundZhong, X., Su, T., Yang, Y., Ye, L., Jiang, L., Qi, Y., Xie, J., Jiang, Y., Zhou, W., Zhang, C., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad149 · Cited by 17
Anaplerosis in cancer: Another step beyond the warburg effect
Ochoa-Ruiz, E., & Díaz-Ruiz, R. (2012) · American Journal of Molecular Biology · doi:10.4236/ajmb.2012.24031 · Cited by 19
A computational analysis of S-(2-succino)cysteine sites in proteins
Miglio, G., Sabatino, A., Veglia, E., Giraudo, M. T., Beccuti, M., & Cordero, F. (2015) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2015.11.003 · Cited by 17
Another small molecule in the oncometabolite mix: L-2-Hydroxyglutarate in kidney cancer
Shim, E., & Sudarshan, S. (2015) · Oncoscience · doi:10.18632/oncoscience.165 · Cited by 17
“While IDH mutation is the most well characterized mechanism for D-2HG elevations in cancer, alternate mechanisms may promote D-2HG accumulation in malignancy.”
BackgroundInfluentialSynthetically Lethal Interactions of Heme Oxygenase-1 and Fumarate Hydratase Genes
Podkalicka, P., Mucha, O., Kruczek, S., Biela, A., Andrysiak, K., Stępniewski, J., Mikulski, M., Gałȩzowski, M., Sitarz, K. S., Brzózka, K. D., et al. (2020) · Biomolecules · doi:10.3390/biom10010143 · Cited by 17
Sporadic paraganglioma caused by de novo SDHB mutations in a 6-year-old girl
Imamura, H., Muroya, K., Tanaka, E., Konomoto, T., Moritake, H., SATO, T. A., Kimura, N., Takekoshi, K., & Nunoi, H. (2015) · European Journal of Pediatrics · doi:10.1007/s00431-015-2614-5 · Cited by 17
Hensen, E. F., Goeman, J. J., Oosting, J., van der Meij, A. G. L., Hogendoorn, P. C. W., Cremers, C. W. R. J., Devilee, P., & Cornelisse, C. J. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-25 · Cited by 17
Fumarate Hydratase Deficiency in Monozygotic Twins
Phillips, T., Gibson, J. B., & Ellison, D. A. (2006) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2006.02.005 · Cited by 17
Downregulation of Fumarate Hydratase Is Related to Tumorigenesis in Sporadic Renal Cell Cancer
Ha, Y., Chihara, Y., Yoon, H.-Y., Kim, Y., Kim, T.-H., Woo, S. H., Yun, S. J., Kim, I. Y., Hirao, Y., & Kim, W. (2012) · Urologia Internationalis · doi:10.1159/000345608 · Cited by 17
Rathmell, W. K., Lee, C. M., & Rini, B. I. (2007) · Current Opinion in Oncology · doi:10.1097/cco.0b013e3280ad4388 · Cited by 17
Metabolomics in paraganglioma: applications and perspectives from genetics to therapy
Richter, S., Garrett, T. J., Bechmann, N., Clifton-Bligh, R. J., & Ghayee, H. K. (2023) · Endocrine Related Cancer · doi:10.1530/erc-22-0376 · Cited by 16
Todisco, S., Iacobazzi, D., Santarsiero, A., Convertini, P., & Infantino, V. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102233 · Cited by 16
Jackson, E. R. K., Pointon, O., & Burgess, J. R. (2016) · Clinical Endocrinology · doi:10.1111/cen.13020 · Cited by 16
Bulku, A., Weaver, T. M., & Berkmen, M. B. (2018) · The Open Biochemistry Journal · doi:10.2174/1874091x01812010001 · Cited by 17
Ueno, D., Vasquez, J. C., Sule, A. D., Liang, J., Doorn, J. V., Sundaram, R. K., Friedman, S., Caliliw, R., Ohtake, S., Bao, X., et al. (2022) · Oncotarget · doi:10.18632/oncotarget.28273 · Cited by 16
“FH and SDH are key elements of the Krebs cycle, and loss of function can cause accumulation of the metabolites fumarate and succinate, respectively [10].”
BackgroundMitochondrial complex II regulates a distinct oxygen sensing mechanism in monocytes
Sharma, S., Wang, J., Gomez, E. C., Taggart, R. T., & Baysal, B. E. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx041 · Cited by 16
Pereira, B. D., Silva, T., Bernardo, A. T., César, R., Luíz, H. V., Pacák, K., & Mota‐Vieira, L. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8470642 · Cited by 16
“Loss-of-function mutations in SDHx or FH lead to succinate and fumarate accumulation, respectively, and to a subsequent inhibition of HIF-α hydroxylation, a necessary signal recognition step for its degradation by the VHL protein [42, 43].”
BackgroundMetabolomics in the Diagnosis of Pheochromocytoma and Paraganglioma
Dwight, T., Kim, E., Novos, T., & Clifton-Bligh, R. J. (2019) · Hormone and Metabolic Research · doi:10.1055/a-0926-3790 · Cited by 16
Texture analysis of T2-weighted MRI predicts SDH mutation in paraganglioma
Naganawa, S., Kim, J., Yip, S. S. F., Ota, Y., Srinivasan, A., & Moritani, T. (2020) · Neuroradiology · doi:10.1007/s00234-020-02607-5 · Cited by 16
Teng, C., Kuo, H., & Sze, C. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.07.009 · Cited by 16
“HIF1αpathwaysmodulate the response of the hypoxia, growth factors and oncogenes (Pollard et al., 2005), and have also been proposed as causing overexpression in various types of cancer.”
BackgroundMaxwell, P. H. (2011) · The Journal of Pathology · doi:10.1002/path.2950 · Cited by 15
Sun, Y., Li, J., Zhao, X., Xu, J., Shi, M., & Liu, P. (2019) · PubMed · Cited by 15
Proteomics and metabolomics in cancer drug development
D’Alessandro, A., & Zolla, L. (2013) · Expert Review of Proteomics · doi:10.1586/14789450.2013.840440 · Cited by 15
Neuroendocrine Tumors and Tumor Syndromes in Childhood
Gaal, J., & de Krijger, R. R. (2009) · Pediatric and Developmental Pathology · doi:10.2350/09-04-0635-cp.1 · Cited by 15
“This results in HIF-1a accumulation, which then induces the transcription of hypoxia-inducible genes, comparable to the situation in VHL syndrome [81].”
ResultCosta, B., Dettori, D., Lorenzato, A., Bardella, C., Coltella, N., Martino, C., Cammarata, C., Carmeliet, P., Olivero, M., & Renzo, M. F. D. (2010) · The FASEB Journal · doi:10.1096/fj.09-146928 · Cited by 15
Pekny, J. E., Smith, P. B. W., & Marden, J. H. (2018) · Journal of Experimental Biology · doi:10.1242/jeb.171009 · Cited by 15
“During development and physiological adjustments throughout life, oxygen supply to the tissues is regulated by the hypoxia-inducible factor (HIF) pathway, a feedback loop that uses accumulation of succinate as a signal of insufficient oxygen supply (Pollard et al., 2005; Selak et al., 2005).”
Background15 YEARS OF PARAGANGLIOMA: Metabolism and pheochromocytoma/paraganglioma
Mannelli, M., Rapizzi, E., Fucci, R., Canu, L., Ercolino, T., Luconi, M., & Young, W. F. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0215 · Cited by 15
PHD2Mutation and Congenital Erythrocytosis with Paraganglioma
Eltzschig, H. K., Eckle, T. D. L. G., & Grenz, A. (2009) · New England Journal of Medicine · doi:10.1056/nejmc090088 · Cited by 15
Metabolic Effects of Succinate Dehydrogenase Loss in Cancer
Chatoff, A. G., Kantner, D. S., Snyder, N. W., & Rink, L. A. (2025) · Journal of Cellular Physiology · doi:10.1002/jcp.70066 · Cited by 14
Denu, R. A., Joseph, C. P., Urquiola, E., Byrd, P. S., Yang, R. K., Ratan, R., Zarzour, M. A., Conley, A. P., Araujo, D. M., Ravi, V., et al. (2024) · Cancers · doi:10.3390/cancers16091707 · Cited by 14
“SDH deficiency leads to succinate accumulation, which inhibits prolyl hydroxylases, leading to accumulation of the hypoxia-inducible factor 1 alpha (HIF-1 α ) [13].”
BackgroundAnalysis of SDHD promoter mutations in various types of melanoma
Scholz, S. L., Horn, S., Murali, R., Möller, I., Sucker, A., Sondermann, W., Stiller, M., Schilling, B., Livingstone, E., Zimmer, L., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4665 · Cited by 14
Tuthill, M. H., Barod, R., Pyle, L., Cook, H. T., Chew, S. L., Gore, M. E., Maxwell, P. H., & Eisen, T. G. (2009) · BMJ Case Reports · doi:10.1136/bcr.08.2008.0732 · Cited by 14
Liu, P., Tan, F., Liu, H., Li, B., Lei, T., & Zhao, X. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s241331 · Cited by 14
Zuo, L., Chen, Z., Chen, L., Kang, J., Shi, Y., Liu, L., Zhang, S., Jia, Q., Huang, Y., & Sun, Z. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.750794 · Cited by 14
“Succinate is an inhibitor of prolyl hydroxylase (PHD) (19), which is responsible for hydroxylation of hypoxia-inducible factor 1-alpha (HIF1a), causing its degradation.”
BackgroundNew Insights into TETs in Psychiatric Disorders
Zhan, W., Li, Y., Yuan, J., Zhi, N., Huang, Y., Liu, Y., Zhang, M., Wu, S., & Zhao, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094909 · Cited by 14
“Among them, fumarate has the strongest inhibitory effect, followed by succinate [23].”
Background
Metadata
- Authors
- Pollard, P. J., Brière, J. J., Alam, N. A., Barwell, J., Barclay, E., Wortham, N. C., Hunt, T., Mitchell, M., Olpin, S., Moat, S. J., Hargreaves, I. P., Heales, S. J., Chung, Y. L., Griffiths, J. R., Dalgleish, A., McGrath, J. A., Gleeson, M. J., Hodgson, S. V., Poulsom, R., Rustin, P., & Tomlinson, I. P. M.
- Affiliations
- St Thomas' Hospital (GB)
- Cancer Research UK (GB)
- Sheffield Children's Hospital (GB)
- University Hospital of Wales (GB)
- National Hospital for Neurology and Neurosurgery (GB)
- St George's Hospital (GB)
- Guy's Hospital (GB)
- Inserm (FR)
- Corresponding author
- Pollard, P.J.
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-06-29
- Volume
- 14
- Issue
- 15
- Pages
- 2231-2239
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2136749294
- Cited by
- 865
- References
- 39
- Citations by year
- 2026: 28 · 2025: 26 · 2024: 15 · 2023: 29 · 2022: 37 · 2021: 48 · 2020: 37 · 2019: 56 · 2018: 48 · 2017: 34 · 2016: 47 · 2015: 58 · 2014: 52 · 2013: 55 · 2012: 48
- FWCI
- 12.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Human Molecular Genetics (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Research Portal (King's College London) (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion)
- Funders
- Cancer Research UK
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Surgery › Adrenal and Paraganglionic Tumors
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Keywords
- fumarate hydratase, succinate dehydrogenase, Krebs cycle intermediates, fumarate accumulation, succinate accumulation, HIF-1α stabilization, hereditary leiomyomatosis and renal cell carcinoma, paraganglioma, pheochromocytoma, leiomyoma, microvessel density, vascular endothelial growth factor, reactive oxygen species
- MeSH terms
- Carcinoma, Renal Cell, Citric Acid Cycle, Female, Fumarate Hydratase, Humans, Leiomyoma, Neoplasms, Paraganglioma, Succinate Dehydrogenase, Tumor Cells, Cultured, Germ-Line Mutation, Vascular Endothelial Growth Factor A
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.